Business Wire

CA-TALKDESK

4.6.2024 15:01:27 CEST | Business Wire | Press release

Share
Talkdesk Unveils New Generative Artificial Intelligence Capabilities to Hyper-Personalize Customer Experience

Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, is leading the charge to rid the world of bad CX with the launch of generative AI (GenAI)-powered Talkdesk Navigator and mood insights, today at Customer Contact Week Las Vegas 2024.

Harnessing the power of GenAI, Talkdesk is paving the way for hyper-personalized customer experiences that dynamically adjust content, offers, and recommendations based on each customer's unique profile, history, usage patterns, location, demographics, and even current emotional state. Talkdesk Navigator makes it simple to create new, as well as improve existing, customer journeys, providing brands with intuitive, conversational, and context-aware interaction orchestration. Mood insights, a feature of Talkdesk Interaction Analytics™, evaluates customers' emotional states throughout an interaction, speeding time to resolution and improving customer satisfaction.

Talkdesk Navigator provides GenAI-powered routing and is the first point of contact when customers engage with customer support or sales. It autonomously manages and prioritizes incoming inquiries based on real-time context. Using natural conversation, Talkdesk Navigator can understand customer requests and then automatically deliver the ideal experience for every customer, every time.

Customers simply tell Talkdesk Navigator what they need or want to accomplish, in their own words, without being forced into complex, rigid, and frustrating interactive voice response (IVR) menus. For administrators, Talkdesk Navigator eliminates the tedious setup and iterations required to build natural, efficient customer experiences. With no training required, it can understand naturally and initiate the most efficient path to resolution.

Talkdesk Interaction Analytics reviews customer conversations for topics and sentiment trends without setup. With GenAI, it detects emerging topics, uncovering valuable insights and opportunities—even the unexpected ones. The addition of mood insights allows contact centers to now capture the complexity of human feelings and provide emotional analysis at the beginning and end of the interaction—and the reason why those emotions may have changed. Agents can better support customers, and operational leaders can understand which behaviors to emphasize in order to improve agent performance

Traditional sentiment analysis generally lumps a customer’s emotional state into three broad categories—positive, negative, and neutral—and neglects the nuances of emotion that often change throughout the interaction. Powered by a large language model (LLM), the Talkdesk GenAI-powered mood insights captures feelings like gratitude, annoyance, and relief. By understanding the reason why customer emotions change during an interaction, contact centers can tailor their interactions and mitigate potential issues more precisely and accurately.

Talkdesk has been serving up practical AI in the contact center since 2018. Talkdesk Navigator and mood insights follow recent introductions of several other groundbreaking and industry-first GenAI innovations in CX from the company, including Talkdesk Ascend Connect, Talkdesk Autopilot for Banking, Talkdesk Autopilot for Retail, and Talkdesk Autopilot for Healthcare.

Supporting Quotes

Zeus Kerravala, founder and principal analyst of ZK Research, commented: “Generative AI has had a profound impact on how companies support and service their customers, and we’re really just beginning to see what’s possible. Talkdesk Navigator and mood insights are at the forefront of this new era of hyper-personalized customer experience that moves us away from hard-to-use interactive voice response systems toward a more natural, customized, and easier engagement with brands. This should be a natural progression for any company looking to transform the customer journey.”

Tiago Paiva, chief executive officer and founder of Talkdesk, said: "Generative AI has opened up new possibilities for CX and is rewriting the rules of customer engagement. Traditional personalization is no longer enough. Customers expect interactions tailored to their unique preferences and emotions. With Talkdesk Navigator and mood insights, we're empowering organizations to deliver hyper-personalized experiences with AI that drive deeper connections that foster lasting customer loyalty."

About Talkdesk

Talkdesk® is on a mission to rid the world of bad customer experience. With our cloud-native, generative AI-powered CX platform, purpose-built industry solutions, and extensible AI offerings, we empower enterprises in the cloud and on-premises to deliver exceptional customer experiences that make them more competitive, grow revenue, reduce costs, and provide operational efficiencies. With specialized workflows and integrations delivered out of the box for our Industry Experience Clouds, Talkdesk accelerates value for our customers faster and more simply than legacy or one-size-fits-all solutions.

Partnering with enterprises globally, we deliver continuous innovation and breakthrough results. Our commitment to reliability and security, paired with our track record of delivering on promises, sets us apart in the industry. Elevate customer experiences, streamline operations, and increase revenue with Talkdesk. Companies that love their customers use Talkdesk.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604367824/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye